艾滋病治疗用药-绥美凯

Today we will learn about the AIDS treatment drug-Inbec. Inbec has been approved in more than 100 countries and has been recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong, said, "Through effective HIV drug treatment, the lifespans of HIV patients and healthy people are getting closer and closer. Drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day, one tablet at a time, on the Chinese market. The approval of Inbec fills this gap and meets the urgent need for convenient medication use by doctors and patients."

Inbec is indicated for the treatment of adults and adolescents over 12 years of age (who weigh at least 40 kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir.

Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.

HIV is a virus that attacks the body's immune system. It takes the most important CD4 T lymphocytes in the human immune system as its main attack target, destroys these cells in large quantities, and causes the human body to lose its immune function. Therefore, the human body is susceptible to various diseases, and malignant tumors can occur, with a high mortality rate. The average incubation period of HIV in the human body is 8 to 9 years.

In 2018, GSK announced the launch of the integrase DTG (Inbec) in China. This treatment has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. Inbec uses DTG, an integrase inhibitor, as the core drug, and combines it with abacavir and lamivudine as a treatment plan. It is made into a single-tablet treatment and promoted, making the core drug a great progress in HAART treatment. Inbec can significantly reduce the burden of medication for AIDS patients, thereby improving their medication compliance and effectively improving their quality of life and work.